Cell-free DNA screening for trisomy 21 in twin pregnancy : a large multicenter cohort study
Copyright © 2023. Published by Elsevier Inc..
BACKGROUND: Analysis of cell-free DNA from maternal blood provides effective screening for trisomy 21 in singleton pregnancies. Data on cell-free DNA screening in twin gestations are promising although limited. In previous twin studies, cell-free DNA screening was primarily performed in the second trimester and many studies did not report chorionicity.
OBJECTIVE: This study aimed to evaluate the screening performance of cell-free DNA for trisomy 21 in twin pregnancies in a large, diverse cohort. A secondary aim was to evaluate screening performance for trisomy 18 and trisomy 13.
STUDY DESIGN: This was a retrospective cohort study of twin pregnancies from 17 centers for which cell-free DNA screening was performed from December 2011 to February 2020 by one laboratory using massively parallel sequencing technology. Medical record review was conducted for all newborns and data on the birth outcome, the presence of any congenital abnormalities, phenotypic appearance at birth, and any chromosomal testing that was undertaken in the antenatal or postnatal period were extracted. Cases with a possible fetal chromosomal abnormality with no genetic test results were reviewed by a committee of maternal-fetal medicine geneticists. Cases with a vanishing twin and inadequate follow-up information were excluded. A minimum of 35 confirmed cases of trisomy 21 was required to capture a sensitivity of at least 90% with a prevalence of at least 1.9% with 80% power. Test characteristics were calculated for each outcome.
RESULTS: A total of 1764 samples were sent for twin cell-free DNA screening. Of those, 78 cases with a vanishing twin and 239 cases with inadequate follow-up were excluded, leaving a total of 1447 cases for inclusion in the analysis. The median maternal age was 35 years and the median gestational age at cell-free DNA testing was 12.3 weeks. In total, 81% of the twins were dichorionic. The median fetal fraction was 12.4%. Trisomy 21 was detected in 41 of 42 pregnancies, yielding a detection rate of 97.6% (95% confidence interval, 83.8-99.7). There was 1 false negative and no false positive cases. Trisomy 21 was detected in 38 out of 39 dichorionic twin pregnancies, yielding a detection rate of 97.4% (95% confidence interval, 82.6-99.7). Trisomy 18 was detected in 10 of the 10 affected pregnancies. There was 1 false positive case. Trisomy 13 was detected in 4 of the 5 cases, yielding a detection rate of 80% (95% confidence interval, 11.1-99.2). There was one false negative and no false positive cases. The nonreportable rate was low at 3.9 %.
CONCLUSION: Cell-free DNA testing is effective in screening for trisomy 21 in twin gestations from the first trimester of pregnancy. Detection of trisomy 21 was high in dichorionic and monochorionic twins, and the nonreportable result rates were low. This study included high numbers of cases of trisomy 18 and 13 when compared with the current literature. Although screening for these conditions in twins seems to be promising, the numbers were too small to make definitive conclusions regarding the screening efficacy for these conditions. It is possible that cell-free DNA testing performance may differ among laboratories and vary with screening methodologies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:229 |
|---|---|
| Enthalten in: |
American journal of obstetrics and gynecology - 229(2023), 4 vom: 15. Okt., Seite 435.e1-435.e7 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dugoff, Lorraine [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 29.09.2023 Date Revised 12.10.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ajog.2023.04.002 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355350777 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355350777 | ||
| 003 | DE-627 | ||
| 005 | 20231226064149.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ajog.2023.04.002 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1184.xml |
| 035 | |a (DE-627)NLM355350777 | ||
| 035 | |a (NLM)37030426 | ||
| 035 | |a (PII)S0002-9378(23)00229-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dugoff, Lorraine |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cell-free DNA screening for trisomy 21 in twin pregnancy |b a large multicenter cohort study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.09.2023 | ||
| 500 | |a Date Revised 12.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023. Published by Elsevier Inc. | ||
| 520 | |a BACKGROUND: Analysis of cell-free DNA from maternal blood provides effective screening for trisomy 21 in singleton pregnancies. Data on cell-free DNA screening in twin gestations are promising although limited. In previous twin studies, cell-free DNA screening was primarily performed in the second trimester and many studies did not report chorionicity | ||
| 520 | |a OBJECTIVE: This study aimed to evaluate the screening performance of cell-free DNA for trisomy 21 in twin pregnancies in a large, diverse cohort. A secondary aim was to evaluate screening performance for trisomy 18 and trisomy 13 | ||
| 520 | |a STUDY DESIGN: This was a retrospective cohort study of twin pregnancies from 17 centers for which cell-free DNA screening was performed from December 2011 to February 2020 by one laboratory using massively parallel sequencing technology. Medical record review was conducted for all newborns and data on the birth outcome, the presence of any congenital abnormalities, phenotypic appearance at birth, and any chromosomal testing that was undertaken in the antenatal or postnatal period were extracted. Cases with a possible fetal chromosomal abnormality with no genetic test results were reviewed by a committee of maternal-fetal medicine geneticists. Cases with a vanishing twin and inadequate follow-up information were excluded. A minimum of 35 confirmed cases of trisomy 21 was required to capture a sensitivity of at least 90% with a prevalence of at least 1.9% with 80% power. Test characteristics were calculated for each outcome | ||
| 520 | |a RESULTS: A total of 1764 samples were sent for twin cell-free DNA screening. Of those, 78 cases with a vanishing twin and 239 cases with inadequate follow-up were excluded, leaving a total of 1447 cases for inclusion in the analysis. The median maternal age was 35 years and the median gestational age at cell-free DNA testing was 12.3 weeks. In total, 81% of the twins were dichorionic. The median fetal fraction was 12.4%. Trisomy 21 was detected in 41 of 42 pregnancies, yielding a detection rate of 97.6% (95% confidence interval, 83.8-99.7). There was 1 false negative and no false positive cases. Trisomy 21 was detected in 38 out of 39 dichorionic twin pregnancies, yielding a detection rate of 97.4% (95% confidence interval, 82.6-99.7). Trisomy 18 was detected in 10 of the 10 affected pregnancies. There was 1 false positive case. Trisomy 13 was detected in 4 of the 5 cases, yielding a detection rate of 80% (95% confidence interval, 11.1-99.2). There was one false negative and no false positive cases. The nonreportable rate was low at 3.9 % | ||
| 520 | |a CONCLUSION: Cell-free DNA testing is effective in screening for trisomy 21 in twin gestations from the first trimester of pregnancy. Detection of trisomy 21 was high in dichorionic and monochorionic twins, and the nonreportable result rates were low. This study included high numbers of cases of trisomy 18 and 13 when compared with the current literature. Although screening for these conditions in twins seems to be promising, the numbers were too small to make definitive conclusions regarding the screening efficacy for these conditions. It is possible that cell-free DNA testing performance may differ among laboratories and vary with screening methodologies | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Down syndrome | |
| 650 | 4 | |a aneuploidy | |
| 650 | 4 | |a cell-free DNA | |
| 650 | 4 | |a noninvasive prenatal screening | |
| 650 | 4 | |a noninvasive prenatal testing | |
| 650 | 4 | |a screening | |
| 650 | 4 | |a trisomy | |
| 650 | 4 | |a trisomy 21 | |
| 650 | 4 | |a twin | |
| 650 | 7 | |a Cell-Free Nucleic Acids |2 NLM | |
| 700 | 1 | |a Koelper, Nathanael C |e verfasserin |4 aut | |
| 700 | 1 | |a Chasen, Stephen T |e verfasserin |4 aut | |
| 700 | 1 | |a Russo, Melissa L |e verfasserin |4 aut | |
| 700 | 1 | |a Roman, Ashley S |e verfasserin |4 aut | |
| 700 | 1 | |a Limaye, Meghana A |e verfasserin |4 aut | |
| 700 | 1 | |a Ranzini, Angela C |e verfasserin |4 aut | |
| 700 | 1 | |a Clifford, Caitlin M |e verfasserin |4 aut | |
| 700 | 1 | |a Biggio, Joseph R |c Jr |e verfasserin |4 aut | |
| 700 | 1 | |a Subramaniam, Akila |e verfasserin |4 aut | |
| 700 | 1 | |a Seasely, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Patil, Avinash S |e verfasserin |4 aut | |
| 700 | 1 | |a Weed, Samantha |e verfasserin |4 aut | |
| 700 | 1 | |a Page, Jessica M |e verfasserin |4 aut | |
| 700 | 1 | |a Nicholas, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Idler, Jay |e verfasserin |4 aut | |
| 700 | 1 | |a Rao, Rashmi R |e verfasserin |4 aut | |
| 700 | 1 | |a Crowder, Amber |e verfasserin |4 aut | |
| 700 | 1 | |a Shree, Raj |e verfasserin |4 aut | |
| 700 | 1 | |a McLennan, Graham |e verfasserin |4 aut | |
| 700 | 1 | |a Bromley, Bryann |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of obstetrics and gynecology |d 1945 |g 229(2023), 4 vom: 15. Okt., Seite 435.e1-435.e7 |w (DE-627)NLM000012343 |x 1097-6868 |7 nnns |
| 773 | 1 | 8 | |g volume:229 |g year:2023 |g number:4 |g day:15 |g month:10 |g pages:435.e1-435.e7 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ajog.2023.04.002 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 229 |j 2023 |e 4 |b 15 |c 10 |h 435.e1-435.e7 | ||